KAPA — Kairos Pharma, Ltd. Dilution Risk Tracker

Kairos Pharma, Ltd. (KAPA) has a DilutionScore of 61/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 13, 2026, updated from SEC EDGAR data.

KAPA has an active ATM (at-the-market) program with $15.0M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event. Cash runway is a key watch item: KAPA has approximately 13 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for KAPA in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for KAPA alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.